Bone loss after oophorectomy among high-risk women

An NRG oncology/gynecologic oncology group study

Elizabeth A. Hibler, James Kauderer, Mark H. Greene, Gustavo C. Rodriguez, David S Alberts

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Women undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss. Methods: The Gynecologic Oncology Group (GOG)-0215 randomized phase-II trial of zoledronic acid was initiated to determine if postoophorectomy bisphosphonate therapy could prevent this bone loss. The study was closed after slow accrual prevented evaluation of the primary study endpoint. We analyzed changes in bone mineral density (BMD) among the 80 women randomized to the observation arm of this study, as measured 3, 9, and 18 months postenrollment. Results: The mean change in BMD from baseline to 18 months was-0.09 (95% CI,-0.12 to-0.07),-0.05 (95% CI,-0.07 to-0.03), and-0.06 (95% CI,-0.07 to-0.05) g/cm2 across the lumbar spine, right hip, and left hip, respectively. This represents a BMD decrease of-8.5% for the lumbar spine and-5.7% for both the right and left hips from baseline to 18 months' observation. Conclusions: These results demonstrate that premenopausal women undergoing oophorectomy clearly experience bone loss, an adverse effect of oophorectomy, which requires attention and active management. BMD should be monitored postoophorectomy, and treated per standard practice guidelines. Future studies will be required to determine if early treatment can mitigate fracture risk, and to test promising therapeutic interventions and novel prevention strategies, such as increased physical activity or alternative medications, in randomized trials.

Original languageEnglish (US)
Pages (from-to)1228-1232
Number of pages5
JournalMenopause
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Ovariectomy
Bone Density
Hip
Bone and Bones
zoledronic acid
Spine
Observation
Diphosphonates
Practice Guidelines
Ovarian Neoplasms
Arm
Therapeutics
Exercise
Breast Neoplasms

Keywords

  • Bone mineral density
  • Oophorectomy
  • Premenopausal

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Bone loss after oophorectomy among high-risk women : An NRG oncology/gynecologic oncology group study. / Hibler, Elizabeth A.; Kauderer, James; Greene, Mark H.; Rodriguez, Gustavo C.; Alberts, David S.

In: Menopause, Vol. 23, No. 11, 01.11.2016, p. 1228-1232.

Research output: Contribution to journalArticle

Hibler, Elizabeth A. ; Kauderer, James ; Greene, Mark H. ; Rodriguez, Gustavo C. ; Alberts, David S. / Bone loss after oophorectomy among high-risk women : An NRG oncology/gynecologic oncology group study. In: Menopause. 2016 ; Vol. 23, No. 11. pp. 1228-1232.
@article{4ae886dfa189487098168683313b4a84,
title = "Bone loss after oophorectomy among high-risk women: An NRG oncology/gynecologic oncology group study",
abstract = "Objective: Women undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss. Methods: The Gynecologic Oncology Group (GOG)-0215 randomized phase-II trial of zoledronic acid was initiated to determine if postoophorectomy bisphosphonate therapy could prevent this bone loss. The study was closed after slow accrual prevented evaluation of the primary study endpoint. We analyzed changes in bone mineral density (BMD) among the 80 women randomized to the observation arm of this study, as measured 3, 9, and 18 months postenrollment. Results: The mean change in BMD from baseline to 18 months was-0.09 (95{\%} CI,-0.12 to-0.07),-0.05 (95{\%} CI,-0.07 to-0.03), and-0.06 (95{\%} CI,-0.07 to-0.05) g/cm2 across the lumbar spine, right hip, and left hip, respectively. This represents a BMD decrease of-8.5{\%} for the lumbar spine and-5.7{\%} for both the right and left hips from baseline to 18 months' observation. Conclusions: These results demonstrate that premenopausal women undergoing oophorectomy clearly experience bone loss, an adverse effect of oophorectomy, which requires attention and active management. BMD should be monitored postoophorectomy, and treated per standard practice guidelines. Future studies will be required to determine if early treatment can mitigate fracture risk, and to test promising therapeutic interventions and novel prevention strategies, such as increased physical activity or alternative medications, in randomized trials.",
keywords = "Bone mineral density, Oophorectomy, Premenopausal",
author = "Hibler, {Elizabeth A.} and James Kauderer and Greene, {Mark H.} and Rodriguez, {Gustavo C.} and Alberts, {David S}",
year = "2016",
month = "11",
day = "1",
doi = "10.1097/GME.0000000000000692",
language = "English (US)",
volume = "23",
pages = "1228--1232",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Bone loss after oophorectomy among high-risk women

T2 - An NRG oncology/gynecologic oncology group study

AU - Hibler, Elizabeth A.

AU - Kauderer, James

AU - Greene, Mark H.

AU - Rodriguez, Gustavo C.

AU - Alberts, David S

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective: Women undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss. Methods: The Gynecologic Oncology Group (GOG)-0215 randomized phase-II trial of zoledronic acid was initiated to determine if postoophorectomy bisphosphonate therapy could prevent this bone loss. The study was closed after slow accrual prevented evaluation of the primary study endpoint. We analyzed changes in bone mineral density (BMD) among the 80 women randomized to the observation arm of this study, as measured 3, 9, and 18 months postenrollment. Results: The mean change in BMD from baseline to 18 months was-0.09 (95% CI,-0.12 to-0.07),-0.05 (95% CI,-0.07 to-0.03), and-0.06 (95% CI,-0.07 to-0.05) g/cm2 across the lumbar spine, right hip, and left hip, respectively. This represents a BMD decrease of-8.5% for the lumbar spine and-5.7% for both the right and left hips from baseline to 18 months' observation. Conclusions: These results demonstrate that premenopausal women undergoing oophorectomy clearly experience bone loss, an adverse effect of oophorectomy, which requires attention and active management. BMD should be monitored postoophorectomy, and treated per standard practice guidelines. Future studies will be required to determine if early treatment can mitigate fracture risk, and to test promising therapeutic interventions and novel prevention strategies, such as increased physical activity or alternative medications, in randomized trials.

AB - Objective: Women undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss. Methods: The Gynecologic Oncology Group (GOG)-0215 randomized phase-II trial of zoledronic acid was initiated to determine if postoophorectomy bisphosphonate therapy could prevent this bone loss. The study was closed after slow accrual prevented evaluation of the primary study endpoint. We analyzed changes in bone mineral density (BMD) among the 80 women randomized to the observation arm of this study, as measured 3, 9, and 18 months postenrollment. Results: The mean change in BMD from baseline to 18 months was-0.09 (95% CI,-0.12 to-0.07),-0.05 (95% CI,-0.07 to-0.03), and-0.06 (95% CI,-0.07 to-0.05) g/cm2 across the lumbar spine, right hip, and left hip, respectively. This represents a BMD decrease of-8.5% for the lumbar spine and-5.7% for both the right and left hips from baseline to 18 months' observation. Conclusions: These results demonstrate that premenopausal women undergoing oophorectomy clearly experience bone loss, an adverse effect of oophorectomy, which requires attention and active management. BMD should be monitored postoophorectomy, and treated per standard practice guidelines. Future studies will be required to determine if early treatment can mitigate fracture risk, and to test promising therapeutic interventions and novel prevention strategies, such as increased physical activity or alternative medications, in randomized trials.

KW - Bone mineral density

KW - Oophorectomy

KW - Premenopausal

UR - http://www.scopus.com/inward/record.url?scp=84978745082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978745082&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000692

DO - 10.1097/GME.0000000000000692

M3 - Article

VL - 23

SP - 1228

EP - 1232

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 11

ER -